1. Europe PMC. URL: https://europepmc.org/article/NBK/nbk572088. Accessed on [March 30, 2023]
2. European Medicines agency. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq. Accessed on [March 30, 2023].
3. Related substances method development and validation of Axitinib, Zanubrutinib and Upadacitinib using RP-HPLC and its degradation products were characterized by using LC-MS/MS;Ibrahim;Int J Pharm Investig,2023
4. Quantification of the Janus kinase 1 inhibitor Upadacitinib in human plasma by LC-MS/MS;Martens-Lobenhoffer;J Chromatogr B,2022
5. Quantification of an anti-rheumatic agent: Upadacitinib in biological fluid (plasma) by LC-MS/MS;Venkateswara Rao;J Pharm Negat Results,2022